Impact of diabetes mellitus on the outcomes of subjects with hypertrophic cardiomyopathy: a nationwide cohort study
Hypertrophic cardiomyopathy (HCM) is a relatively common genetic cardiomyopathy caused by sarcomeric gene mutations with an assumed prevalence of 1 in 200 persons,[1] and is characterized by left ventricular hypertrophy unexplained by other secondary causes. The clinical course of HCM is complicated by sudden cardiac death, heart failure, atrial fibrillation, and embolic stroke.[2 –4] With advances in management strategies including implantable cardioverter-defibrillators and anticoagulation, subjects with hypertrophic cardiomyopathy (HCM) are benefiting from extended longevity.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Hyun-Jung Lee, Hyung-Kwan Kim, Bong-Seong Kim, Kyung-Do Han, Tae-Min Rhee, Jun-Bean Park, Heesun Lee, Seung-Pyo Lee, Yong-Jin Kim Source Type: research
More News: Atrial Fibrillation | Cardiology | Cardiomyopathy | Diabetes | Diabetes Mellitus | Endocrinology | Genetics | Heart | Heart Failure | Hypertrophic Cardiomyopathy | Stroke | Study